A new era for castrate resistant prostate cancer: A treatment review and update
- 16 February 2012
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 18 (3), 343-354
- https://doi.org/10.1177/1078155212437599
Abstract
Purpose: The purpose of this review article is to present the current treatment options for castrate resistant prostate cancer in addition to the recently approved agents and their role in treatment. Summary: The biology of prostate cancer and the data supporting the use of traditional chemotherapeutic options in castrate resistant prostate cancer are reviewed. The newly approved agents, sipuleucel-T, cabazitaxel, and abiraterone, are presented as well. The studies that led to the approval of these three agents are discussed in this article as well as their current and potential roles in the treatment of castrate resistant prostate cancer. Conclusion: New mechanisms, drugs, and clinically relevant molecular targets show survival advantage and are new options available for patients after traditional chemotherapy. The roles of these new agents have yet to be further clarified in future studies.Keywords
This publication has 61 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole TherapyJournal of Clinical Oncology, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancerAnnals Of Oncology, 2009
- Antiandrogen withdrawal in castrate‐refractory prostate cancerCancer, 2008
- Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation TherapyJournal of General Internal Medicine, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003